Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Current Assets (2019 - 2025)

Bioadaptives' Current Assets history spans 7 years, with the latest figure at $211901.0 for Q4 2025.

  • Quarterly results put Current Assets at $211901.0 for Q4 2025, down 19.09% from a year ago — trailing twelve months through Dec 2025 was $211901.0 (down 19.09% YoY), and the annual figure for FY2025 was $211901.0, down 19.09%.
  • Current Assets for Q4 2025 was $211901.0 at Bioadaptives, up from $108860.0 in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $261885.0 in Q4 2024 to a low of $8735.0 in Q2 2024.
  • The 5-year median for Current Assets is $69252.5 (2021), against an average of $91171.3.
  • The sharpest move saw Current Assets plummeted 82.29% in 2023, then skyrocketed 2825.19% in 2025.
  • Year by year, Current Assets stood at $88876.0 in 2021, then tumbled by 61.38% to $34324.0 in 2022, then soared by 158.0% to $88557.0 in 2023, then soared by 195.72% to $261885.0 in 2024, then decreased by 19.09% to $211901.0 in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $211901.0, $108860.0, and $255515.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.